XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2021
Mar. 31, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K/A    
Amendment Flag true    
Document Period End Date Dec. 31, 2021    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Trading Symbol CBIO    
Entity Registrant Name Catalyst Biosciences, Inc.    
Entity Central Index Key 0001124105    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Accelerated Filer    
Entity Shell Company false    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Common Stock, Shares Outstanding   31,477,053  
Entity Public Float     $ 135,045,079
ICFR Auditor Attestation Flag true    
Entity Interactive Data Current Yes    
Title of 12(b) Security Common stock, par value $0.001 per share    
Security Exchange Name NASDAQ    
Entity File Number 000-51173    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 56-2020050    
Entity Address, Address Line One 611 Gateway Blvd    
Entity Address, Address Line Two Suite 710    
Entity Address, City or Town South San Francisco    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94080    
City Area Code 650    
Local Phone Number 871-0761    
Document Annual Report true    
Document Transition Report false    
Auditor Firm ID 274    
Auditor Name EisnerAmper LLP    
Auditor Location Philadelphia, Pennsylvania    
Amendment Description EXPLANATORY NOTE Catalyst Biosciences, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-K/A (“Amendment”) to amend its Annual Report on Form 10-K for the year ended December 31, 2021 (the “Form 10-K”), which was originally filed with the Securities and Exchange Commission (“SEC”) on March 31, 2022. The purpose of this Amendment is to file the information required by Items 10, 11, 12, 13 and 14 of Part III of Form 10-K. Except as described above, no other amendments are being made to our annual report on Form 10-K filed on March 31, 2022. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), new certifications by the Company’s principal executive officer and principal financial officer are filed herewith as exhibits 31.03 and 31.04 to this Amendment pursuant to Rule 13a-14(a) of the Exchange Act. The Company is not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) as no financial statements are being filed with this Amendment.